The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 144.40
Bid: 144.60
Ask: 145.00
Change: -0.40 (-0.28%)
Spread: 0.40 (0.277%)
Open: 138.00
High: 145.00
Low: 138.00
Prev. Close: 144.80
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Chromium business

30 Nov 2022 07:00

RNS Number : 0013I
Elementis PLC
30 November 2022
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (EU) No.596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via a regulatory information service, this inside information is now considered to be in the public domain.

London, 30 November, 2022.

Elementis plc

Sale of Chromium business

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today announces that it has agreed to sell its Chromium business to Yildirim Group for an enterprise value of US$170m. The transaction includes the transfer of environmental liabilities of $35m and other liabilities of $8m, with the total cash proceeds on completion expected to be around $119m before tax, after all transaction costs and subject to customary closing working capital adjustments. The transaction is subject to US regulatory approval, which is expected before the end of Q1 2023. 

The sale follows the strategic review of the Chromium business announced in April 2022. In the twelve months to 30 June 2022, the Chromium business reported Sales of $171m and Adjusted Operating Profit of $14m (including $7m of Group costs allocated to Chromium). The transaction values the Chromium business at 7.3 times EBITDA (12-months to 30 June 2022). The transaction will result in a gain on disposal, and a tax charge of approximately $12m. The majority of the Group costs previously allocated to Chromium are expected to be phased out by the end of 2023.

Following the sale of the Chromium business, Elementis will continue to implement its strategy built on innovation, growth and efficiency, with a portfolio now fully focused on premium specialty products. In the twelve months to 30 June 2022 this portfolio delivered underlying sales growth of 14%, adjusted operating profit of $125m, and an adjusted operating margin of 17.0% (excluding corporate costs). 

The cash proceeds from the sale will be used to reduce the Group's Net Debt, in line with the capital allocation priorities. Group Net Debt at 30 June 2022 was $393m, representing 2.4x EBITDA (excluding the impact of IFRS16), and pro-forma Net Debt/EBITDA (after reflecting the Chromium transaction) was 2.0x, closer to the Group's medium-term target of 1.5x.

Paul Waterman, CEO of Elementis commented:

"Whilst Chromium has been a part of Elementis for many years, our strategic review concluded that the interests of all stakeholders would now be best served by a sale of the business. Our Personal Care, Coatings and Talc businesses are focused on developing advantaged, high-value products to drive revenue growth and margin expansion. Going forward, I'm confident the focused implementation of our Innovation, Growth & Efficiency strategy positions us to deliver on our medium-term financial objectives and generate significant shareholder value.

Chromium is an attractive business with a strong market position, but it increasingly sat outside of this strategic framework. We are confident that Yildirim will take the business forward in the best long-term interests of its customers and employees."

 

 

A virtual presentation for investors and analysts will be held at 14.00 GMT on 30 November 2022. The presentation will be web-cast on www.elementis.com and a copy of this announcement can also be found on this website. 

Webcast link: https://www.investis-live.com/elementis/637e19dc7c7f0c1300c1e019/xcvg

Conference call dial-in details :

UK: 020 3936 2999

USA: 1 646 664 1960

All other Locations: +44 20 3936 2999

Access Code: 939292

Enquiries

Elementis plc

David Boyd, Investor Relations Tel: +44 7764 905135

David.boyd.ext@elementis.com

 

Juliana Noronha, Corporate Communications Tel: +44 7384 866389

Juliana.noronha@elementis.com 

 

Tulchan

Martin Robinson, Olivia Peters Tel: 020 7353 4200

Olivia Peters

 

 

 

NOTES TO EDITORS:

About Elementis

Elementis is a global specialty chemical company, with 1,400 employees operating at 22 manufacturing sites across the globe. Elementis works with its customers to solve their product performance and sustainability challenges, developing and delivering solutions that make customer's products easier to manufacture and perform better.

Combining its leading positions in the science of materials flow, surface modification, and formulation with its access to unique natural materials and its global footprint, Elementis delivers Enhanced Performance Through Applied Innovation to customers in a wide range of markets, including cosmetics, anti-perspirants, decorative and industrial coatings, automotive and ceramics. In 2021 Elementis reported revenue of $880m and adjusted operating profit of $107m.

About Yildirim Group

Yildirim Group is a leading Dutch-Turkish industrial group headquartered in Istanbul and Amsterdam, focusing on metals and mining, port management, fertilizers and chemicals, green energy, shipping and logistics, construction and infrastructure, and private equity financing. Yildirim has more than 20,000 employees in 55 countries on 5 continents.

Yildirim Group's metals and mining business is a major producer of chrome ore and high-carbon ferrochrome. Yildirim owns and operates chrome mines, ferrochrome and various ferroalloy production plants in Turkey, Sweden, Kazakhstan, Russia, Albania, and Kosovo.

About the Chromium business

The Chromium business operates from five manufacturing sites in the United States and employs approximately 240 people. The largest site is at Castle Hayne in North Carolina which produces Sodium Dichromate and Chromic Acid. These products are then transported to the four other sites, one of which produces Chrome Oxide and the other three Chrome Sulfate.

Elementis is the only Chromium producer in the Americas, with a leading market share in the North Americas region, which represents the majority of sales. Chromium products provide strength and prevent corrosion and are used primarily in the metal plating, timber treatment, coatings, leather tanning and other industries. Elementis has developed a unique system of product delivery to customers via railcar or truck, which is significantly safer than traditional transportation methods.

Chromium production is an energy intensive business, with the Chromium business accounting for 73% of the Group's greenhouse gas emissions in 2021. Gross assets of the Chromium business at the end of 2021 were $153.2 million.

Eaglescliffe site (UK)

This transaction excludes the remaining assets and liabilities of the UK Chromium business which ceased operations in 2009. This comprises the 480 acre Eaglescliffe site in County Durham, for which the Group has provisions of $29m, based on analysis provided by specialist site remediation companies. Other commercial opportunities for the Eaglescliffe site are currently being explored.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISPPGPGGUPPPPB
Date   Source Headline
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.